Literature DB >> 21037250

Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.

Jens Jakob Thune1, James E Signorovitch, Lars Kober, John J V McMurray, Karl Swedberg, Jean Rouleau, Aldo Maggioni, Eric Velazquez, Robert Califf, Marc A Pfeffer, Scott D Solomon.   

Abstract

UNLABELLED: IMS: Recurrent myocardial infarction (MI) is common after a first MI and is associated with increased morbidity and mortality. Predictors and prognosis of a recurrent MI with contemporary management are not well known. METHODS AND
RESULTS: We assessed the predictors and prognostic impact of a first recurrent MI in 10,599 patients with left ventricular dysfunction, heart failure, or both following a first MI from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) cohort. During a median follow-up of 27.4 months, 861 patients (9.6%) had a recurrent MI. The median time to recurrence was 136 days (quartiles 35-361 days), with a declining rate of recurrent MI within the first 3 months. The strongest predictors of recurrent MI were reduced estimated glomerular filtration rate, unstable angina, diabetes, and age. Mortality was markedly elevated (20.5%) within the first 7 days of a recurrent MI. Patients who survived 7 days after a recurrent MI continued to be at increased risk of death compared with patients without a recurrent MI and the risk of death remained elevated more than two-fold a year after the recurrent MI (adjusted hazards ratio 2.4, 95% confidence interval 1.7-3.2). One-year mortality for the entire VALIANT cohort was 10.3%, whereas 38.3% of the patients were dead 1 year after recurrent MI. Early reinfarctions (within 1 month) was associated with significantly higher 30-day mortality than later reinfarctions.
CONCLUSION: Even in the context of contemporary treatment, a recurrent MI confers a significantly increased risk of death in patients following a high-risk first MI. Strategies aimed at reducing recurrent MI will thus likely prolong survival in post-MI survivors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21037250     DOI: 10.1093/eurjhf/hfq194

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  21 in total

1.  Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes.

Authors:  S Oddi; M Bari; N Battista; D Barsacchi; I Cozzani; M Maccarrone
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

2.  Sex Differences in the Risk of Developing Acute Coronary Syndrome in Patients With Sleep Disorders: A Population-Based Cohort Study.

Authors:  Wei-Sheng Chung; Hsuan-Hung Lin
Journal:  Am J Mens Health       Date:  2016-05-26

Review 3.  Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis.

Authors:  Alexander C Fanaroff; Vic Hasselblad; Matthew T Roe; Deepak L Bhatt; Stefan K James; Ph Gabriel Steg; C Michael Gibson; E Magnus Ohman
Journal:  Int J Cardiol       Date:  2017-03-14       Impact factor: 4.164

4.  Novel Mechanisms of Exosome-Mediated Phagocytosis of Dead Cells in Injured Heart.

Authors:  Mallikarjun Patil; Sherin Saheera; Praveen K Dubey; Asher Kahn-Krell; Prem Kumar Govindappa; Sarojini Singh; Sultan Tousif; Qinkun Zhang; Hind Lal; Jianyi Zhang; Gangjian Qin; Prasanna Krishnamurthy
Journal:  Circ Res       Date:  2021-10-08       Impact factor: 23.213

5.  Timing and long-term prognosis of recurrent MI after primary angioplasty : Stent thrombosis vs. non-stent-related reinfarction.

Authors:  A Viveiros Monteiro; R Ramos; A Fiarresga; L de Sousa; D Cacela; L Patrício; L Bernardes; C Soares; R Cruz Ferreira
Journal:  Herz       Date:  2016-06-30       Impact factor: 1.443

Review 6.  Acute myocardial infarction leads to acceleration of atherosclerosis.

Authors:  Hui Wang; Daniel T Eitzman
Journal:  Atherosclerosis       Date:  2013-04-12       Impact factor: 5.162

Review 7.  Mind-Body Medicine in the Secondary Prevention of Coronary Heart Disease.

Authors:  Holger Cramer; Romy Lauche; Anna Paul; Jost Langhorst; Andreas Michalsen; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-11-06       Impact factor: 5.594

8.  Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans.

Authors:  Hamed Emami; Parmanand Singh; Megan MacNabb; Esad Vucic; Zachary Lavender; James H F Rudd; Zahi A Fayad; Joshua Lehrer-Graiwer; Magnus Korsgren; Amparo L Figueroa; Jill Fredrickson; Barry Rubin; Udo Hoffmann; Quynh A Truong; James K Min; Amos Baruch; Khurram Nasir; Matthias Nahrendorf; Ahmed Tawakol
Journal:  JACC Cardiovasc Imaging       Date:  2015-01-07

9.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

10.  MiRNA and TF co-regulatory network analysis for the pathology and recurrence of myocardial infarction.

Authors:  Ying Lin; Vusumuzi Leroy Sibanda; Hong-Mei Zhang; Hui Hu; Hui Liu; An-Yuan Guo
Journal:  Sci Rep       Date:  2015-04-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.